ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2019
Biomimetic Nanotherapies: Red Blood Cell Based Core-Shell Structured Nanocomplexes for Atherosclerosis Management.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 133 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
133 citing papers in PubMed.
- Reprogramming innate immunity through viral interference: A double-edged strategy for enhancing and containing gene therapies.Molecular therapy. Nucleic acids · 2026Review
- Nanomedicine-based theranostics in atherosclerotic cardiovascular diseases.Journal of biomedical science · 2026Review
- Transformative biomechanics and mechanobiology breakthroughs shaping the future of health and medicine.Innovation (Cambridge (Mass.)) · 2026Review
- Lipid-based nanosystems for atherosclerosis treatment: Evolving approaches and novel therapeutic strategies.Acta pharmaceutica Sinica. B · 2026Review
- Mesenchymal stem cell membrane-coated kaempferol biomimetic nanoformulation for the treatment of atherosclerosis.APL bioengineering · 2026Article
- Recent Advances in Nanoparticle-Based Drug Delivery Strategies to Cross the Blood-Brain Barrier in Targeted Treatment of Alzheimer's Disease.Pharmaceutics · 2026Review
- Restoring immune homeostasis in atherosclerotic plaques via inorganic violet phosphorus nano-immunotherapy.Cell reports. Medicine · 2026Article
- Advancements in dual-targeting nanoparticle strategies for enhanced atherosclerosis therapy: Overcoming limitations of single-targeting approaches.Bioactive materials · 2026Review
- Delivery of TCM Monomers Using Blood Cell Membrane Coated Biomimetic Nanoparticles to Target CVD.International journal of nanomedicine · 2026Review
- Reprogramming mitochondrial metabolism and epigenetics of macrophages via miR-10a liposomes for atherosclerosis therapy.Nature communications · 2025Article
- Innovative nanocarriers: Synthetic and biomimetic strategies for enhanced drug delivery.Materials today. Bio · 2025Review
- Engineered hybrid cell membrane nanosystems for treating cardiovascular diseases.Materials today. Bio · 2025Review
- Recent advances in biomimetic nanodelivery systems for cancer Immunotherapy.Materials today. Bio · 2025Review
- The potential of erythrocyte-mimic nanoparticles in the treatment of cardiovascular diseases.Nanomedicine (London, England) · 2025Article
- Pitavastatin-loaded procyanidins self-assembled nanoparticles alleviate advanced atherosclerosisActa pharmaceutica Sinica. B · 2025Article
- Synthetic Polymers for Drug, Gene, and Vaccine Delivery.Polymer science & technology (Washington, D.C.) · 2025Review
- Polymeric Nanomaterials for Atherosclerosis Diagnosis and Treatment.Polymer science & technology (Washington, D.C.) · 2025Review
- A polymerized probucol nanoformulation with neutrophil extracellular vesicle camouflage for cerebral ischemia-reperfusion injury therapy.Innovation (Cambridge (Mass.)) · 2025Article
- Application of therapeutical nanoparticles with neutrophil membrane camouflaging for inflammatory plaques targeting against atherosclerosis.Materials today. Bio · 2025Article
- Using nanotechnology for the diagnosis and treatment of coronary artery disease: a narrative review.The British journal of cardiology · 2025Article
73 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease is the leading cause of mortality worldwide. Atherosclerosis, one of the most common forms of the disease, is characterized by a gradual formation of atherosclerotic plaque, hardening, and narrowing of the arteries. Nanomaterials can serve as powerful delivery platforms for atherosclerosis treatment. However, their therapeutic efficacy is substantially limited in vivo due to nonspecific clearance by the mononuclear phagocytic system. In order to address this limitation, rapamycin (RAP)-loaded poly(lactic-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.